Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
National Institutes of Health Clinical Center (CC)
Tango Therapeutics, Inc.
Instituto do Cancer do Estado de São Paulo
Vastra Gotaland Region
Seagen Inc.
Genmab
KaliVir Immunotherapeutics
Fudan University
Tango Therapeutics, Inc.
Beijing Biotech
IDEAYA Biosciences
Vivace Therapeutics, Inc
AstraZeneca
iOnctura
Sotio Biotech Inc.
Massachusetts General Hospital
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
University Health Network, Toronto
Endeavor Biomedicines, Inc.
Nuvectis Pharma, Inc.
A2 Biotherapeutics Inc.
Zhejiang University
National Institutes of Health Clinical Center (CC)
University of Chicago
University Hospital, Lille
Royal Marsden NHS Foundation Trust
PrECOG, LLC.
Takeda